Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Phase 3 urcosimod therapy for neuropathic corneal pain
OKYO Pharma is a clinical-stage biopharmaceutical company developing topical therapies for neuropathic corneal pain and other ocular surface conditions. Its lead candidate, urcosimod (formerly OK-101), is a chemerin receptor agonist designed to modulate inflammation and corneal pain signalling. Phase 2a testing…
AI-driven drug discovery targeting intrinsically disordered proteins
Peptone is a translational biophysics company developing novel therapeutics against intrinsically disordered proteins (IDPs), a class of structurally dynamic proteins implicated in cancer, inflammation and metabolic disease. The company combines hydrogen-deuterium exchange mass spectrometry, high-performance…
Constrained bicyclic peptide conjugates for targeted cancer therapy
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of therapeutics based on short synthetic peptides constrained by a small molecule scaffold into two loops, conferring high-affinity target binding with the tissue penetration of small molecules. Its lead programme, a…
Oral microbiome therapeutics for gastrointestinal and hepatic disease
EnteroBiotix is a clinical-stage biopharmaceutical company developing orally delivered, full-spectrum microbiome therapeutics for diseases linked to gut microbiome disruption. Its lead asset EBX-102-02 demonstrated clinically meaningful improvements in irritable bowel syndrome in Phase 2a trials, with a Phase 2b study…
Engineered biologics with conditional activation for precision cancer immunotherapy
Switch Biologics is a UK biotechnology company developing engineered protein biologics for cancer immunotherapy. The company applies directed evolution and protein engineering to build conditionally activated therapeutics that respond to two simultaneous molecular signals, a design intended to concentrate activity…
UK generic and branded medicine manufacturer supplying the NHS nationwide
Crescent Pharma is an independent generic pharmaceutical company developing, manufacturing and supplying medicines to the NHS, pharmacies, hospitals and healthcare providers across the UK and internationally. The company holds several hundred UK marketing authorisations and operates multiple manufacturing sites,…
Small molecule drug discovery platform focused on immuno-inflammation
C4X Discovery (C4XD) is a UK drug discovery company developing small molecule drug candidates using its proprietary computational and structural chemistry platform. It applies enhanced candidate molecule design and patient stratification capabilities to generate drug candidates across immuno-inflammatory disease…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to engineer Tregs with enhanced persistence and potency. Its lead candidate QEL-001 is in the Phase 1/2 LIBERATE trial for liver transplant…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…
Precision bacteriocin antibiotics targeting drug-resistant Gram-negative pathogens
Glox Therapeutics is a Scottish biotech developing a pipeline of engineered protein bacteriocins as precision antibiotics against drug-resistant Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Spun out of the Universities of Glasgow and Oxford in 2023, the company…
siRNA therapeutics targeting liver-expressed disease genes
Silence Therapeutics is a clinical-stage biotechnology company developing siRNA therapeutics using its proprietary platform. The platform enables precise silencing of disease-associated genes expressed in the liver, without permanently altering DNA. Its pipeline addresses cardiovascular disease, haematological…
Autologous platelet-based biotherapies for chronic wound healing
Biotherapy Services is a clinical-stage company developing autologous biotherapies for wound healing and tissue regeneration. Its lead treatment is a gel prepared at the point of care from a concentrate of the patient's own platelets, activated with the patient's own thrombin to release growth factors and other…
ML-driven antibody discovery platform for solid tumour therapeutics
LabGenius Therapeutics is a company developing next-generation therapeutic antibodies using its closed-loop machine learning platform. The platform integrates AI, robotic automation and high-throughput experimentation to co-optimise multispecific antibodies across potency, selectivity and manufacturability…
Clinical-stage biopharma targeting cancer immunotherapy and obesity
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing small molecule therapies for high unmet medical needs. Its lead programme, POLB 001, is a p38 MAP kinase inhibitor in clinical trials for prevention of cytokine release syndrome associated with CAR-T and bispecific antibody cancer immunotherapies.…
Nanotechnology drug delivery platform for precision medicines
Nanomerics is a UK speciality pharmaceutical company developing precision medicines using its proprietary technology, a polymer nanotechnology platform that improves the bioavailability and targeting of water-insoluble drugs and peptides. The technology enables delivery via nasal, ocular, oral, and blood-brain barrier…
First-in-class small molecule inhibitors of RNA-modifying enzymes
STORM Therapeutics is a clinical-stage biotechnology company pioneering the field of RNA epigenetics, developing small molecule inhibitors of RNA-modifying enzymes as a new class of cancer treatment. Its lead programme STC-15, a METTL3 inhibitor, was the first RNA-modifying enzyme inhibitor to enter human clinical…
Extracellular vesicle platform for consistent, scalable regenerative therapeutics
Mesenbio is a preclinical-stage biopharmaceutical company developing a cell line platform that produces a consistent, scalable supply of therapeutic extracellular vesicles, addressing a key bottleneck limiting this treatment class. The company's cells generate naturally bioactive vesicles with combined…
TCR bispecific immunotherapies for cancer and infectious disease
Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…
Oncology drug discovery and IP licensing from rural Wales
Morvus Technology is a privately owned pharmaceutical company engaged in the discovery, development, and out-licensing of novel oncology drugs and platform technologies. The company's portfolio includes ProTide nucleoside chemistry, out-licensed to NuCana plc for clinical development; an inhaled anti-tumour agent for…
AstraZeneca's rare disease arm targeting the complement cascade
Alexion, AstraZeneca Rare Disease is the rare disease group within AstraZeneca, formed following the 2021 acquisition of Alexion Pharmaceuticals. With nearly 30 years of rare disease heritage, the division focuses on novel molecules targeting the complement cascade across haematology, nephrology, neurology, metabolic…